THCV vs CBN: The Energy and Sleep Claims
One is sold to put you to sleep, the other to get you going, and the evidence treats them just as differently. CBN's sleep claim has been tested in people and came up short. THCV's energy and appetite claims have no primary evidence behind them in our registry. On intoxication, CBN is at most weakly intoxicating, while THCV's action at CB₁ shifts with the dose. Demonstrated · in vitro
Grades follow the evidence behind each statement. Legal notes are general and dated, and they are not legal advice; this page makes no therapeutic claim for either compound.
Side by side
| Attribute | THCV (tetrahydrocannabivarin) | CBN (cannabinol) |
|---|---|---|
| Marketed for | THCV (tetrahydrocannabivarin)Energy, focus and appetite control, sold as "diet weed" | CBN (cannabinol)Sleep, often in blends with melatonin |
| Evidence for that claim | THCV (tetrahydrocannabivarin)No primary evidence in a person in our registry · No primary evidence | CBN (cannabinol)Tested in people, and the pre-specified endpoints were missed (Bonn-Miller 2024; Lavender 2026) · Not supported |
| Intoxicating? | THCV (tetrahydrocannabivarin)Cannot be relied on as non-intoxicating; the effect depends on dose (Pertwee 2008) · Demonstrated · in vitro | CBN (cannabinol)Ranges from non-intoxicating to weakly intoxicating at most; receptor activity is weak in lab studies · Demonstrated · in vitro |
| Where it comes from | THCV (tetrahydrocannabivarin)The three-carbon ("varin") relative of THC | CBN (cannabinol)Forms as THC ages and oxidises · Established |
| Molecular formula | THCV (tetrahydrocannabivarin)C₁₉H₂₆O₂ (CAS 31262-37-0) | CBN (cannabinol)C₂₁H₂₆O₂ (CAS 521-35-7) |
| Drug testing | THCV (tetrahydrocannabivarin)Tests screen for THC, not THCV. Many THCV products contain trace THC, and how THCV itself behaves on a test has not been characterised · Established | CBN (cannabinol)A real risk. CBN can cross-react with THC immunoassays, and CBN products can carry trace THC · Established |
| Safety data | THCV (tetrahydrocannabivarin)Limited, with long-term safety not established · Catalogue in progress | CBN (cannabinol)Trials measured short-term side effects; long-term and interaction data are unpublished · Catalogue in progress |
| US legal status (general, dated; not legal advice) | THCV (tetrahydrocannabivarin)Complicated by total-THC rules that are still changing; differs by state | CBN (cannabinol)Hemp-derived CBN at ≤0.3% Δ⁹-THC is generally federally legal under the 2018 Farm Bill; differs by state |
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- THCV: blocks, and at higher doses activates (direction reverses with dose), in a review, no rung of its own study type: Review Pertwee 2008. CBN: no graded interaction in our registry.
- CB2 cannabinoid receptor
- THCV: activates (partial agonist; an earlier paper reports the opposite), in a review, no rung of its own study type: Review Pertwee 2008. CBN: no graded interaction in our registry.
- α2-adrenoceptor
- THCV: no graded interaction in our registry. CBN: no graded interaction in our registry.
- 5-HT1A serotonin receptor
- THCV: no graded interaction in our registry. CBN: no graded interaction in our registry.
- TRPV1 and TRPV2 ion channels
- THCV: no graded interaction in our registry. CBN: no graded interaction in our registry.
- TRPM8 ion channel
- THCV: no graded interaction in our registry. CBN: no graded interaction in our registry.
What the evidence settles
Sleep and energy sit at opposite ends of the day, and the two claims sit at opposite ends of the record: CBN's has trial data against it, THCV's has an empty file in our registry.
- Sleep: tested, and not supported. CBN has had its turn in human sleep trials, and those trials missed the endpoints they pre-specified (Bonn-Miller 2024; Lavender 2026). A few lower-ranked outcomes moved, but a missed primary endpoint stays missed. The trials were run, they came up short, and a sleep claim for CBN now runs against the data. Not supported
- Energy and appetite: no primary evidence. THCV sells as an energiser and as "diet weed", yet our registry holds zero primary evidence that it changes energy, appetite or body weight in a person, and it is not classified as a stimulant. No primary evidence
- Intoxication. CBN ranges from non-intoxicating to weakly intoxicating at most, with weak activity at cannabinoid receptors in lab studies. THCV is harder to pin down. In living animals it acts as a CB₁ antagonist, or as a CB₁ agonist at higher doses (Pertwee 2008), so any "non-intoxicating" promise on a THCV product hangs on the dose. Demonstrated · in vitro
- Drug testing. For buyers who get tested, CBN is the bigger worry: it can cross-react with the immunoassays used in standard screens, and CBN products can carry trace THC. THCV products can carry trace THC as well, and nobody has characterised how THCV itself behaves on a test. Established
- Origins. Both are THC relations, by different routes. CBN forms as THC ages and oxidises; THCV is THC's three-carbon "varin" relative. Established
Common questions
Is THCV or CBN better for sleep?
Neither, on the evidence. CBN is the one tested for sleep in people, and those trials missed their pre-specified endpoints (Bonn-Miller 2024; Lavender 2026). The lower-ranked outcomes that moved can't make up for a missed primary endpoint, so the claim is graded Not-supported. THCV gets no sleep claim from us at all. Not medical advice. Not supported
Does THCV give you energy?
Nothing we hold shows that it does. THCV is marketed as energising or clear-headed, and some users report those effects anecdotally, but controlled human studies have not established them. It is also not classified as a stimulant. Not medical advice. No primary evidence
Do THCV or CBN get you high?
CBN does not produce THC's high and is at most weakly intoxicating; THCV depends on the dose. In animals THCV acts as a CB₁ antagonist, and at higher doses as an agonist (Pertwee 2008). No human threshold for that switch has been established. Demonstrated · in vitro
Will THCV or CBN show up on a drug test?
CBN is a real risk, and THCV a possible one. CBN can cross-react with standard THC immunoassays, and CBN products can carry trace THC. Tests look for THC rather than THCV, but many THCV products contain trace THC, and how THCV itself behaves on a test remains poorly characterised. Established
Are THCV and CBN legal?
Often, in the US, with caveats. Hemp-derived CBN at ≤0.3% Δ⁹-THC is generally federally legal under the 2018 Farm Bill. THCV sits in murkier water, caught up in total-THC rules that are still changing, and states differ. General information, not legal advice. [Legal snapshot · not legal advice]
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Sources
- Pertwee et al. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. PMID 17828291.
- Bonn-Miller et al. (2024). A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Exp Clin Psychopharmacol. PMID 37796540.
- Lavender et al. (2026). Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. J Sleep Res. PMID 41698831.
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons